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Abstract It is generally believed that mammalian pyruvate 
dehydrogenase kinase is a heterodimer consisting of catalytic and 
regulatory subunits. However, the contribution of the two 
subunits to the kinase-mediated signal transduction has remained 
undefined. In the present study recombinant components of 
mammalian pyruvate dehydrogenase complex were employed in 
order to characterize the role of the kinase catalytic subunit in 
the regulation of pyruvate dehydrogenase reaction. The results 
provide the first evidence strongly suggesting that the catalytic 
subunit of pyruvate dehydrogenase kinase is competent to 
respond to known effectors of kinase activity as well as to 
interact with the E2-core without assistance of a regulatory 
subunit. 
© 1997 Federation of European Biochemical Societies. 
Key words: Pyruvate dehydrogenase complex; Pyruvate 
dehydrogenase kinase; Regulation; Metabolism of 
carbohydrates 
1. Introduction 
Pyruvate dehydrogenase kinase (PDK) catalyzes phospho-
rylation of the mitochondrial pyruvate dehydrogenase com-
plex (PDC) that leads to its complete inactivation. By this 
means, PDK serves as an efficient tool to control flux through 
the complex and, in turn, the rate of aerobic oxidation of 
carbohydrates (for review see [1-3]). The enzymatic activity 
of PDK is regulated by an array of compounds that are sub-
strates, products and co-factors of the pyruvate dehydrogen-
ase reaction. As a general rule, the products of dehydrogenase 
reaction activate, while the substrates inhibit PDK activity. 
This allows the kinase to sense the metabolic need for carbo-
hydrates catabolism and accordingly adjust the activity of 
PDC [1]. The exact molecular mechanisms that are employed 
by most of the effectors in order to regulate kinase activity 
have not been elucidated entirely. It is believed that only 
pyruvate inhibits PDK activity directly via binding to a spe-
cialized allosteric site on the kinase molecule [4,5]. The effects 
of NAD+, NADH, CoA and acetyl-CoA, in contrast, have 
been proposed to be indirect [6], mediated by the lipoyl-pros-
thetic groups covalently attached to the PDC core [7]. 
Structurally, PDK purified from bovine kidney appears to 
consist of two non-equivalent subunits with molecular weights 
of 48000 and 45 000 Da [8]. Elegant experiments with selective 
digestion of the 48 000 Da subunit by chymotrypsin and the 
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45 000 Da subunit by trypsin established that the catalytic 
function of PDK is associated with the 48 000 Da subunit. 
The function of the 45 000 Da subunit has not been deter-
mined, but it was suggested that it may be responsible for 
targeting of the catalytic subunit to the complex and/or for 
the allosteric regulation of the kinase activity [8]. The evidence 
for a regulatory subunit has made the status of PDK's cata-
lytic subunit uncertain for want of data on whether it can 
interact with the PDC core and also respond to physiologi-
cally relevant effectors in the absence of the regulatory sub-
unit. 
Recently, this laboratory made considerable progress in the 
molecular cloning and expression of cDNAs encoding isoen-
zymes of the catalytic subunit of PDK [9]. This, along with 
recent success in the expression and reconstitution of the PDC 
from recombinant proteins [10], allowed me to take another 
look at the regulation of PDK activity using completely de-
fined, recombinant components of the mammalian PDC. The 
present manuscript reports the effects of different components 
of PDC on the enzymatic activity of the recombinant catalytic 
subunit of PDK along with the first evidence that the catalytic 
subunit itself is competent to respond to effectors of PDK 
activity. 
2. Materials and methods 
2.1. Expression and purification of rat PDK 
The molecular cloning of the cDNA encoding for the rat isoenzyme 
2 of PDK (RPDK2) was reported previously [11]. The construction of 
the bacterial expression vector based on pET-28a (Novagen) was re-
ported in [9]. Expression and purification of the His-tagged RPDK2 
was performed essentially as described elsewhere [9] with some mod-
ifications. Briefly, the expressing E. coli strain was allowed to grow at 
37°C in M9ZB media containing 45 ug/ml kanamycin and 35 ug/ml 
chloramphenicol until OD600 reached 0.7-0.8. At this point, the cul-
ture was transferred to room temperature and induced with 0.4 mM 
isopropyl ß-D-thiogalactopyranoside (IPTG). After 20-24 h of induc-
tion, cells were harvested by centrifugation and resuspended in 10 
volumes of TN buffer (20 mM Tris-HCl, pH 8.0, 0.1 M NaCl) sup-
plemented with 10 mM ß-mercaptoethanol, 0.5% (w/v) Triton X-100, 
and a cocktail of protease inhibitors (0.1 mM phenylmethylsulfonyl 
fluoride, 0.1 mM benzamidine, 20 ug/ml pepstatin A, 20 ug/ml leu-
peptin, and 1% (v/v) aprotinin). Cells were disrupted by sonication (5 
times for 20 s with 1 min intervals for cooling on ice). Extracts were 
clarified by centrifugation at 50000Xg for 30 min at 4°C. Recombi-
nant kinase was purified on a 5 ml bed volume of TALON resin 
(Clontech) following the manufacturer's instructions. Affinity purified 
kinase (approximately 5-10 mg of protein) was immediately supple-
mented with 5 mM dithiothreitol (DTT), desalted on a PD-10 column 
(Pharmacia) equilibrated in 25 mM Tris-HCl (pH 8.0) containing 0.5 
mM EDTA, 5 mM DTT, 0.05% Triton X-100 (TEDT) plus the cock-
tail of protease inhibitors and loaded on MonoQ HR5/5 column 
(Pharmacia) equilibrated in TEDT at flow rate of 1 ml/min. The 
column was consecutively washed with 5 volumes of TEDT and de-
veloped with 20 volumes linear gradient of NaCl (from 0 to 500 mM) 
prepared in TEDT. The kinase containing fractions eluted at NaCl 
concentration of approximately 250-300 mM were pooled, made 50% 
(v/v) with glycerol and stored in small aliquots at —80°C. 
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2.2. Expression and purification of the E¡-Es and E1-E2/E3BP 
subcomplexes of human PDC 
The sources of cDNAs for the components of human PDC and the 
construction of the respective bacterial expression vectors were re-
ported previously [10]. Purification of E1-E2 and E1-E2/E3BP subcom-
plexes was achieved by consecutive polyethyleneglycol-8000 (Sigma) 
fractionation, gel-filtration of Sepharose 4B (Pharmacia) and high-
speed centrifugation. Some of the complexes were further purified 
by chromatography on Bio-Gel HT Gel (Bio-Rad) as described in 
[12]. Resulting preparations were stored at — 80°C in small aliquots. 
Purified preparations of the recombinant human Ei component were 
obtained as a generous gift from Dr. Mulchand S. Patel (Department 
of Biochemistry, SUNY at Buffalo). These preparations were further 
concentrated to the final protein concentration of 1 mg/ml using Cen-
triplus concentrators (Amicon) and stored in small aliquots at — 80°C. 
2.3. PDK activity assay 
Kinase activity was determined by following [32P]phosphate incor-
poration from [y-32P]ATP into the E ia subunit essentially as described 
previously for native PDC [12]. Phosphorylation reactions were set up 
in a final volume of 100 u.1 containing 20 mM Tris-HCl, pH 7.4, 5 mM 
MgCl2, 50 mM KC1, 1 mM ß-mercaptoethanol, 0.1 mg/ml bovine 
serum albumin (BSA), protein substrate, nucleotide substrate (the 
specific activity of [y-32P]ATP was approximately 200-500 cpm/ 
pmol), and 5 ug/ml of the recombinant kinase at 37°C. The protein 
concentrations of the recombinant components of human PDC in the 
assay cocktail were as follows: the Ei (0.5 mg/ml), the E1-E2 subcom-
plex (1.0 mg/ml), and the Ei-E2/E3BP subcomplex (1.0 mg/ml). For 
some experiments, E1-E2/E3BP subcomplex was reconstituted with 
porcine heart E3 component obtained from Sigma (0.1 mg of E3 
per 1.0 mg of E1-E2/E3BP subcomplex) and used as a substrate for 
the recombinant RPDK2 at a final concentration of 1.0 mg/ml. 
Phosphorylation reactions were initiated by addition of ATP after 
equilibration at 37°C for 30 s. Aliquots (20 (xl) of the phosphorylation 
reaction were withdrawn after 20, 40, and 60 s of incubation and 
quenched by applying to dry discs of Whatman No. 3MM paper 
presoaked in 24% (w/v) trichloroacetic acid, 0.2 M phosphoric acid, 
2 mM sodium pyrophosphate, and 1 mM ATP. Protein-bound radio-
activity was determined as described previously [12]. A control (minus 
kinase) was included in each experiment. Kinase activities were calcu-
lated based on incorporation of [32P]phosphate during the first 30 s of 
the reaction. All assays were conducted in triplicates. The rate of 
phosphorylation reaction was proportional to the amount of added 
kinase when RPDK2 was varied from 0.5-2.0 |ig, suggesting that the 
protein substrate is not limiting under the conditions used. The con-
centrations of substrate (ATP) and effectors used in particular experi-
ments are given in Section 3 and in the legends to the figures. Raw 
kinetic data were fitted and analyzed by using Grafit software (Erita-
cus Software). Shown are representative results obtained with one of 
the three preparations of RPDK2 that were analyzed for this study. 
3. Results 
3.1. The effects of Eg or EglEsBP subcomplexes on the 
enzymatic activity of RPDK2 
PDK functions as an integral part of a multienzyme com-
plex and its activity depends upon interaction with other com-
ponents. Accordingly, several laboratories have demonstrated 
that the specific activity of native PDK substantially increases 
when kinase is bound to the complex [2], due presumably to 
tight binding with E2/E3BP-core [7]. In agreement with pre-
vious findings, the catalytic subunit of PDK showed very low 
catalytic efficiency using the recombinant Ei component as a 
substrate, as would be expected for the native enzyme (Fig. 1). 
However, its enzymatic activity increased dramatically in the 
presence of the E2 component, suggesting that, first, the cata-
lytic subunit of the kinase is competent to respond to E2-
mediated activation without the involvement of the regulatory 
subunit and, second, that the transacetylase component alone 
is sufficient to support the enhanced catalytic function of the 
kinase. The E3BP and E3 components were found to be with-
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out any significant effect on kinase activity (Fig. 1). The E3BP 
component had a rather slight inhibitory effect on kinase ac-
tivity. These observations emphasize the previously mentioned 
importance of the transacetylase component of PDC toward 
maintaining enhanced kinase function [7]. They also show that 
the previously reported enhancement of kinase activity is due 
almost exclusively to the transacetylase component, in agree-
ment with conclusions from Roche's laboratory [7]. The E3BP 
component, which has considerable sequence homology to E2 
and was once implicated in the attachment of the kinase to 
the PDC core [13], appears to be without any substantial 
effect on the kinase activity, suggesting that E2 is likely to 
be a primary site of kinase attachment. 
3.2. Regulation of RPDK2 activity by NADH and NADH plus 
acetyl-CoA 
The native kinase from several sources has been shown 
subject to regulation by NAD+/NADH and CoA/acetyl-
CoA ratios [14]. The recombinant catalytic subunit of PDK, 
like its native counterpart, is sensitive to the same type of 
regulation (Fig. 2). When holo-complex obtained by reconsti-
tution of recombinant human E1-E2/E3BP subcomplex with 
native porcine heart E3 component was used as a substrate, 
kinase activity showed a characteristic increase in response to 
products of the dehydrogenase reaction - especially toward 
the simultaneous presence of NADH and acetyl-CoA. The 
transition from a mixture of NAD+ and NADH with a molar 
ratio of 200:1 to a mixture with a molar ratio of 1:3 was 
associated with an approximately two-fold increase in kinase 
activity. The addition of acetyl-CoA to the former mixture of 
NAD+/NADH produced further enhancement that reached 
almost five-fold when compared with kinase activity in the 
presence of NAD+/NADH mixture at a molar ratio of 
200:1 (Fig. 2, left panel). The stimulatory effects of NADH 
and NADH plus acetyl-CoA were apparent when the holo-
PDC (E1-E2/E3BP-E3) was used as the substrate for the cata-
lytic subunit. When the Ei-E2/E3BP subcomplex was used as a 
substrate, there was no apparent effect with neither NADH or 
Subcomplex 
Fig. 1. The effects of E2, E2/E3BP and E2/E3BP-E3 subcomplexes of 
mammalian PDC on the specific activity of recombinant PDK2. 
The activity of RPDK2 was determined essentially as described in 
Section 2 using 100 uM ATP as a substrate. The activity with Ei 
component alone was determined for 2 min of incubation. 
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NADH plus acetyl-CoA on kinase activity (Fig. 2, left panel). 
This observation is in agreement with the previous evidence 
suggesting that the effects of NADH and NADH plus acetyl-
CoA reflect changes in the reduction and acetylated states of 
the lipoyl moieties of PDC [6] rather than direct allosteric 
effects of these compounds on the kinase molecule itself [15]. 
3.3. The effect of dichloroacetate on the activity of RPDK2 
Dichloroacetate (DCA) is one of the most potent and spe-
cific synthetic inhibitors of native PDK. As shown by pioneer-
ing work from Philip Randle's laboratory [4], DCA mimics 
the effect of pyruvate, inhibiting kinase activity via a specific 
inhibitory allosteric site. Detailed kinetic analysis revealed 
that DCA is a non-linear hyperbolic inhibitor of kinase activ-
ity [5]. The mechanism of inhibition is quite complicated in 
that the sensitivity of the kinase to DCA is potentiated by 
ADP, which itself is a competitive inhibitor of kinase activity. 
Binding of the inhibitors is likely to occur in an ordered fash-
ion, with the binding of ADP preceding the binding of DCA 
[5]: 
E + ADP ^ E-ADP + DCA ^ E-ADP-DCA. 
This, in turn, makes it impossible to calculate the apparent K\ 
for DCA from inhibition studies in the absence of ADP. 
Therefore, in the present study the inhibition pattern of the 
recombinant catalytic subunit of PDK was analyzed at multi-
ple concentrations of both inhibitors (DCA and ADP) and the 
respective kinetic data were analyzed by Dixon plot. DCA 
concentration was changed between 0-4.0 mM, and the 
ADP concentration between 0.1-0.8 mM. The concentrations 
of substrates were set at 100 uM for ATP and at 1 mg/ml for 
PDC. Under the described conditions, the inhibition pattern 
of the kinase activity by the two inhibitors was clearly syner-
F,-F,/E,Br-E, E,-li,/£,13P 
Fig. 2. The effect of E3 component on the regulation of PDK2 ac-
tivity by NADH and NADH plus acetyl-CoA. The kinase activity 
was determined as described in Section 2 with the addition of 
NADH and NAD+ in a mixture to a final concentration of 0.6 and 
0.2 mM respectively, and of acetyl-CoA to 50 u.M. Effectors were 
added 30 s prior to ATP in order to allow for equilibration of the 
reactions catalyzed by E2 and E3 components. The final concentra-
tion of ATP was 100 uM. NAD+ controls were made with the ad-
dition of a mixture of NAD+ and NADH (molar ratio 200:1) to 
the final total concentration of 0.8 mM. 
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Fig. 3. Dixon plot of the effect of DCA on ADP inhibition of 
PDK2 activity. Kinase activity was determined without DCA (o) or 
in the presence of 0.5 mM (•), 1.0 mM (D), 2.0 mM (■), or 4.0 
mM ( A ) DCA under conditions described in Section 3. 
gistic (Fig. 3). When both DCA and ADP were present, the 
degree of inhibition was always greater than that observed at 
the same concentrations of DCA or ADP alone (data not 
shown). The apparent K¡ value for DCA obtained from the 
secondary plot (Fig. 3, insert) was approximately 0.2 mM, 
which is almost identical to the apparent K^ value (0.21 
mM) reported for bovine kidney enzyme [5]. In accord with 
observations by Pratt and Roche [5], the inhibition had a non-
linear hyperbolic character. 
4. Discussion 
When mammalian PDK was first purified from bovine kid-
ney mitochondria [8] it appeared to be a heterodimeric en-
zyme consisting of a catalytic and a regulatory subunit. To 
date, the molecular role played by the regulatory subunit has 
not been defined, although it was suggested that it may serve 
as an adaptor that attaches the catalytic subunit to the core of 
the complex and/or mediates the effects of the products and 
substrates of the pyruvate dehydrogenase reaction on enzy-
matic activity of the catalytic subunit [8]. Further progress 
in characterization of the molecular role of the regulatory 
subunit has been slow because of the difficulties in purification 
of native PDK and resolution of its subunits. To complicate 
matters even further, later attempts by this [12] and Philip 
Randle's [16] laboratories to purify PDK from sources other 
than bovine kidney yielded kinase preparations which lacked 
the regulatory component. Surprisingly, these preparations 
appeared to be able to phosphorylate and inactivate PDC, 
and also to respond to effectors of kinase, suggesting that 
the catalytic subunit itself may be competent to carry out 
most of the kinase functions [12]. This conclusion should be 
applied with considerable caution, however, because of uncer-
tainty with respect to the status of the regulatory subunit in 
the preparations of PDC used as substrate in those studies. 
Recent progress in the molecular cloning of cDNAs encoding 
for different components of mammalian PDC [11,12] have 
made PDK and its substrate PDC available as highly purified 
recombinant proteins. This has allowed a re-investigation of 
the regulation of the enzymatic activity of the catalytic sub-
unit of PDK using recombinant proteins of well-defined sub-
unit composition. As reported in the present manuscript, the 
recombinant PDK2, which is the most abundant isoenzyme of 
200 K.M. Popov/FEBS Letters 419 (1997) 197-200 
PDK in kidney, appears to behave in a very similar, if not 
identical, manner to the native kinase from bovine kidney 
mitochondria. Its catalytic activity depends upon interaction 
with the Ei-core (Fig. 1) and is regulated by the products and 
substrates of the dehydrogenase reaction (Fig. 2), essentially 
as described previously for the kidney enzyme. The similarity 
of the recombinant and native kinase was quantitative as well 
as qualitative. For example, the magnitude of stimulation of 
kinase activity by the E2 component, by NADH or by NADH 
plus acetyl-CoA was within the limits reported previously for 
the bovine kidney kinase [14]. Likewise DCA inhibited PDK2 
activity synergistically with ADP, as reported previously for 
native kidney kinase [5]. 
Thus, the results reported here constitute strong evidence 
that the catalytic subunit of PDK is competent to respond to 
effectors of kinase activity, as well as to interact with the PDC 
core without assistance of the regulatory subunit. If one takes 
into account that we and others were unable to purify the 
kinase complexed with the regulatory subunit from heart 
[12] and liver [16] mitochondria, these results suggest that 
the regulatory subunit is not required for the kinase function, 
at least in some tissues. Indeed, the lack of evidence for a 
regulatory subunit in heart and liver raises the question of 
whether such a protein actually exists as an integral compo-
nent of PDC. The fact that preparations of PDK appear to 
consist of several proteins with molecular weights ranging 
from 45 000 to 48000 Da [8,12,13] may simply reflect the 
existence of multiple isoenzymes of PDK in different tissues 
[9]. On the other hand, the original evidence presented by 
Stepp et al. [8] for a regulatory subunit in bovine kidney is 
impossible to dismiss. It is interesting to note in this regard 
that the bovine kidney kinase binds to the complex extremely 
tightly. It remains bound to the E2-core even during gel-filtra-
tion in the presence of solutions of high ionic strength [10]. 
Under comparable conditions the kinase from porcine heart, 
in contrast, appears to dissociate from E2 almost completely 
[17]. These observations indicate that the regulatory subunit 
may be an adaptor that provides extremely strong binding of 
the kinase to the complex. This type of anchoring may be of 
importance for some as yet unidentified reasons in tissues like 
kidney, whereas in others, like heart or liver, the weaker direct 
binding of catalytic subunit to the E2 component may be 
sufficient to elicit the regulatory features of the kinase. 
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